St. John's Wort Versus Placebo in Social Phobia

• Status: Completed
• Trial end date: 2004-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effectiveness of St. John's Wort as compared to placebo (an inactive substance) in the treatment of outpatients with social phobia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Center for Complementary and Integrative Health (NCCIH)

Criteria

Inclusion Criteria:

• Female patients: at least 2 years post-menopausal, surgically sterile, or practicing a medically acceptable method of contraception.

• Meets DSM-IV criteria for Social Phobia, generalized subtype, lasting 12 months in duration (phone screening will determine)

Exclusion Criteria:

• Primary diagnosis of major depression, dysthymia, panic disorder, schizophrenia, schizo-affective disorder, bipolar disorder, or PTSD

• Substance abuse or dependence in the past 6 months

• Vascular dementia or primary degenerative dementia of the Alzheimer's type

• Treatment with MAOIs, TCAs, SSRIs, venlafaxine, nefazodone, remeron, citalopram, or bupropion within 14 days of first visit.

• Fluoxetine within 14 days of first visit.

• Failure to respond to at least two adequate antidepressant trials for social anxiety.

• Investigational drugs within 30 days of baseline

• Known allergy or hypersensitivity to St. John's Wort

• Currently in behavior therapy for Social Phobia

ALL INQUIRIES WILL UNDERGO A PHONE SCREENING TO DETERMINE WHETHER THEY MEET ELIGIBLITY REQUIREMENTS.